Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist

Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535

IDEAYA Biosciences enters license with Hengrui Pharma for a novel phase 1 DLL3 Topo-I-Payload ADC targeting SCLC and NET solid tumors

Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)

Department of Biotechnology hosts webinar on biomanufacturing of enzymes

The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.

Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab

Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India

BASF sells food and health performance ingredients business to Louis Dreyfus Company

Divestment is part of BASF’s strategic portfolio optimization

KRAIBURG TPE's solutions upraises healthcare products for higher functionality

The TPE Tourniquet and TPE Esmark Bandages are renowned for their single-use design,

MSD enters into license agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist

CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA

Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins

Cipla launches India's first inhalable insulin ‘Afrezza’

Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management

Merck to discontinue KeyVibe and Keyform clinical trials

Merck has also decided to end the favezelimab clinical development program